Last reviewed · How we verify
Lung cancer cohort
At a glance
| Generic name | Lung cancer cohort |
|---|---|
| Sponsor | Centre Leon Berard |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance (PHASE2)
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
- AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs
- Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors (PHASE1)
- Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer (PHASE1)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |